Código QR (código de barras bidimensional)

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (SSTR) ligand, radiation can be delivered to cancer...

ver descrição completa

Na minha lista:
Principais autores: Mengqi Shi, Vivianne Jakobsson, Lukas Greifenstein, Pek-Lan Khong, Xiaoyuan Chen, Richard P. Baum, Jingjing Zhang
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2022-12-01
coleção:Frontiers in Medicine
Assuntos:
actinium-225
neuroendocrine tumor
peptide receptor radionuclide therapy (PRRT)
targeted α-particle therapy
SSTR
SSTR antagonist
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fmed.2022.1034315/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados